The U.S. Food and Drug Administration has approved a monthly maintenance dosing regimen for Leqembi, an Alzheimer’s drug developed by Japan’s Eisai and its partner Biogen, the companies announced on Monday. The decision is expected to improve treatment convenience for patients.
FDA Approves Monthly Maintenance Dosing for Alzheimer’s Drug Leqembi
Latest Posts
SouthAsianChronicle
SouthAsianChronicle is an independent digital news platform delivering accurate, timely, and insightful journalism from South Asia and around the world.